[1] 李康保.奥沙利铂联合5-FU、CF 治疗老年Ⅲ期结肠癌的临床 分析[J].临床医学工程, 2011,18(3):345-346. [2] 邓颖. 奥沙利铂的药理作用及临床应用[J]. 吉林医学, 2011,32(18):3707. [3] 易勤根,梁献萍.卡培他滨联合奥沙利铂治疗中晚期结直肠癌临床观察[J].临床和实验医学杂志, 2009,8(11):75-76. [4] 中国抗癌协会食管癌专业委员会.食管癌标准化诊治指南 [M].北京:中国协和医科大学出版社, 2011:112-119. [5] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版) [J].临床肝胆病杂志, 2011,27(11): 1141-1159. [6] 中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会.《中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)》[J].中华血液学杂志, 2013,34 (9): 816-819. [7] Andrew D Z, Jeremy S A, Ranjana H A, et al.Non-Hodgkin’s Lymphomas[J].J Natl Compr Canc Netw,2010,8(3):288-334. [8] Waddell T, Verheij M, Allum W, et al. Arnold.Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2013: 24 (S 6): 57-63. [9] Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J].Ann Oncol, 2015: 26(S 5):116-125. [10] 菅凌燕,何晓静,汪珊.国内外超说明书用药的现状及其启示[J].中华医院管理杂志, 2015,31(1):46-49. [11] Extra J M, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin[J].Semin Oncol, 1998, 25(2 S 5):13-22. [12] 周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,1999:340. [13] Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons[J].Eur J Pharmacol, 2000, 406(1): 25-32. [14] Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind,placebo-controlled trial[J].J Clin Oncol, 2002, 20(16): 3478-3483. |